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ABSTRACT
The persistence of attention-deficit/hyperactivity disorder (ADHO) into
adulthood has been increasingly recognized over the past few decades and the
stimulant drug dl-methylphenidate (MPH) has remained a first-line
pharmacotherapeutic agent in the treatment of ADHD. Many adult ADHD patients
who are prescribed MPH report concomitant use with ethanol.
In humans, coadministration of dl-MPH and ethanol results in pharmacokinetic
and pharmacodynamic drug - drug interactions. Ethanol elevates biological
concentrations of the pharmacologically active d-MPH isomer and yields the
metabolic transesterification product ethylphenidate (EPH). EPH appears to be
formed through the actions of carboxylesterase 1 (CES1) which exhibits I-MPH
substrate enantioselectivity in both the metabolic transesterification and
deesterification pathways. Accordingly, the mean absolute oral bioavailability of
I-MPH is limited to only 1-3°k compared to approximately 30% for d-MPH.
However, dosing with transdermal dl-MPH (Daytrana~ avoids the extensive oral
presystemic metabolism and leads to approximately 50 times more I-MPH
reaching the systemic circulation when compared with oral dosing. Studies using
human subjects are limited in their ability to examine abuse like doses.
Using a C57BU6J mouse model, the experiments in this dissertation were
designed to: 1) Establish the rewarding properties and abuse potential of Lv.
dl-MPH as evidenced by drug seeking behavior; 2) Investigate the
pharmacokinetic interactions of dl-MPH and ethanol coabuse, placing an
emphasis on the MPH transdermal system; 3) Investigate the pharmacodynamic
interactions of dl-MPH and ethanol coabuse.

The reward value of methylphenidate is evidenced by robust drug-seeking
behavior in C57 mice, which are an appropriate model to investigate
methylphenidate abuse liability. Pharmacokinetic studies showed that, as in
humans, transdermal dl-MPH greatly facilitated the absorption of I-MPH in this
mouse strain. Similarly, ethanol led to the enantioselective formation of I-EPH
and to an elevation in d-MPH concentrations with both transdermal and oral dlMPH. While only guarded comparisons between transdermal and oral dl-MPH
can be made due to route-dependent drug absorption rate differences,
transdermal dl-MPH was associated with significant MPH - ethanol interactions.
Pharmacodynamic studies showed that an otherwise depressive dose of ethanol
significantly potentiated oral dl-MPH induced increases in total distance traveled
for the first 100 min. Further, transdermal dl-MPH increased total distance
traveled after a latency of 80 min, though this effect was not potentiated by
concomitant ethanol.
The results from these studies in combination with human data, provide a
scientific basis for extending abuse precautions for the ethanol - dl-MPH
combination in general, with a novel focus on transdermal dl-MPH.

Chapter 1

Introduction

Attention-Deficit/Hyperactivity Disorder: Prevalence & Etiology
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly
diagnosed childhood neuropsychiatric condition and the persistence of ADHD
into adulthood is increasingly recognized [1-6]. Symptoms include inability to
focus or pay attention, hyperactivity, and impulsive behaviors. There are 3
subtypes of ADHD: 1) Predominantly hyperactive-impulsive, 2) Predominately

inattentive, 3) Combined hyperactive-impulse and inattentive [7]. In the
United States, the lifetime prevalence for children and adolescents has been
estimated to range upward to 9.00/0 [8]; and for adults the incidence appears
to exceed 4% [9]. Boys are significantly more likely to be diagnosed with
ADHD than girls [10], however recent studies suggest that this phenomenon
could be in part due to subjectivity in referrals made by teachers [11].
There is no single cause for ADHD, however a number of factors can
contribute to or worsen ADHD symptoms. These factors include: a genetic
predisposition where prominent candidate genes include those expressing the
D4 postsynaptic dopamine receptor and/or the presynaptic dopamine
transporter (OAT), poor diet, neurochemical imbalances, e.g., dopamine
and/or norepinephrine, and the social/physical environment.
Treatments
Following a diagnosis of ADHD, most patients undergo a combination
of behavioral modifications and pharmacotherapy. There are two nonstimulant medications that are FDA approved in the treatment of ADHD,

2

atomoxetine (Strattera®) and guanfacine (Intuniv®). Atomoxetine is a
selective norepinephrine reuptake inhibitor that is not a controlled substance,
however disadvantages include rare, but severe, liver damage and suicide
ideation [12]. Further, this drug is primarily metabolized by CYP2D6 whereby
pharmacogenetic polymorphisms may become clinically significant in dose
individualization. Guanfacine is an alpha-2 agonist and its mechanism of
action appears to be through feedback inhibition of norepinephrine synaptic
release. Only the extended-release formulation is FDA approved in the
treatment of ADHD and the potential for cardiovascular side effects should be
considered prior to use [13].
More commonly, ADHD patients are prescribed stimulant medications,
e.g. methylphenidate (MPH) or amphetamine. Amphetamine is typically
viewed as a 2 nd line agent to treat ADHD not responsive to MPH. There are
numerous amphetamine formulations used in the treatment of ADHD. These
include "mixed amphetamine salts" composed of dl-amphetamine in an
unusual 75% d- : 25% I-mixture of isomer; a prodrug derivative where damphetamine is converted to a lysine amide for reduced abuse potential and
reported improvement in pharmacokinetic properties; and finally formulations
containing only the more active d-isomer of amphetamine. As with most
stimulant medications, abuse, dependence, and cardiovascular adverse
events are major clinical consideration in the use of ADHD stimulants [14].
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The racemic (50:50 mixture of enantiomers) stimulant drug dl-MPH
(Figure 1. 1) has remained the first-line pharmacotherapeutic agent to treat
ADHD since the 1950s [3, 15-16]. MPH is generally an effective and well
tolerated drug in the treatment of ADHD.
In the adult ADHD population, dl-MPH is also the most widely
prescribed psychotherapeutic agent [5]. As a consequence, this controlled
substance has become more widely available for abuse and diversion [17-19],
especially among high school [20] and college students [21-22]. Appropriate
drug therapy for an older ADHD population requires a special consideration of
lifestyle and lifespan comorbidities [5], such as hypertension [21,23], where
elevation of blood pressure by dl-MPH can represent a contraindication.

H 0
II

C-OCH,

H

d-MPH

I-MPH
Figure 1.1 Enantiomers of MPH
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Methylphenidate Pharmacokinetics
MPH is available both as an immediate-release tablet as well as in various
modified-release formulations. The drug is subject to extensive and
enantioselective presystemic metabolism. In humans, oral dl-MPH dosing
results in only -30% of the d-isomer and -1 % of the I-isomer reaching the
systemic circulation. Mass balance studies conducted in humans and rodents
demonstrate that -90+% of the drug is hydrolyzed to the inactive [24]
metabolite ritalinic acid [25], -1-2% is p-hydroxylated, -5% is oxidized to the
corresponding lactam, and -1-20/0 is excreted unchanged. MPH is not subject
to metabolic isomerization. MPH exhibits the relatively short (2 ...3 h) half-life of
2-3 h largely due to the rapid hydrolysis of the methyl ester. Accordingly, most
ADHD patients receiving immediate-release tablets require multiple daily
doses to maintain symptom control[15]. This creates many issues related to
convenience, compliance, peer ridicule and security of this schedule II
narcotic, i.e., diversion. For these reasons, many MPH formulations
incorporate a range of modified-release pharmaceutical technologies to allow
for single daily dosing.
In 2006, the FDA approved the first transdermal patch for the
administration of dl-MPH (Daytrana~. Like the modified-release oral
formulations, the transdermal patch overcomes the need for multiple daily
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dosing regimens, in this case by delivering in continuous release of dl-MPH
throughout the 9 h recommended wear time (Figure 1.2).
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Figure 1.2 Plasma d-MPH and I-MPH (inset) concentration profiles
for 12.5 (0),25 (0 ), and 37.5 cm 2 (~) transdermal methylphenidate
compared to 54 mg Concerta® (X) [26].
This dl-MPH transdermal delivery system relies on a high load of dlMPH free base incorporated within a uniform blend of acrylic polymers and
silicone adhesives to drive drug absorption based on the drug concentration
gradient, without the need for permeability enhancers (for review see [16]) .
Using transdermal delivery of dl-MPH circumvents the extensive and highly
enantioselective presystemic metabolism associated with oral dosing [27-28] .

6

This results in transdermal dl-MPH producing approximately 50 times higher
plasma I-MPH concentrations than occurs following oral dosing (Figure 1.2)

[29].
Methylphenidate: Interactions with Ethanol
Optimized adult ADHD pharmacotherapy may be complicated by
alcohol consumption, alcohol use disorder (AUD) or other substance use
disorders (SUD). SUD are over-represented in adult ADHD [1, 30-31]. The
rewarding properties of dl-MPH have not been fully characterized and in light
of the significant over-representation of SUD, e.g., AUD in adult ADHD, first
line therapies such as dl-MPH require investigation of their abuse potential in
the context of ethanol use and misuse.
In drug diversion, dl-MPH is reported to be co-abused with ethanol in
the majority of users surveyed [18]. . Not surprisingly, dJ-MPH related
emergency department visits number in the thousand each year [19].
Accordingly, prescribing dl-MPH has generated special concern regarding
concomitant ethanol use or abuse [32-34]. This concern stems from the coabuse of cocaine and ethanol as a precedent. Cocaine and methylphenidate
are similar in their pharmacokinetic and pharmacodynamic profiles, where
both increase extracellular dopamine through blockade of the OAT as well as
increasing subjective reports of feeling "high" [18]. Both drugs contain a
methyl ester metabolized by carboxylesterase 1 yielding a carboxylic acid

7

metabolite and, upon coadministration of ethanol, a transesterification
metabolite [35].
Thus, coadministration of ethanol and dl-MPH orally to humans [27,
36] results in a drug - drug interaction where the methyl ester of MPH is
transesterified to yield ethylphenidate (EPH; Figure 1.2) [27]. Both EPH and
ritalinic acid formation appear to be primarily mediated by the actions of
carboxylesterase 1 (CES1) [37-39] which exhibit I-MPH substrate
enantioselectivity in both the transesterification and hydrolysis pathways [27,
40].

~Ritaliaic
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Figure 1.2 Metabolic fate of dl-MPH with or without ethanol.
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Any I-MPH, or the metabolite I-EPH, which reaches system circulation
is unlikely to contribute directly to the pharmacodynamics of the dl-MPH ethanol interaction in view of the findings that only the d-isomers of MPH and
EPH possess potent effects on dopaminergic and noradrenergic systems [4041].
In a recent human study, coadministration of dl-MPH and ethanol
resulted in a significant elevation of maximum plasma d-MPH concentrations
(C max) and overall d-MPH exposure [27]. Elevated plasma d-MPH
concentrations increase the potential for adverse cardiovascular events [4243] due to the fact ·that the d-isomer is responsible for adrenergic pressor
effects. In addition to the influence of ethanol on dl-MPH pharmacokinetics,
the above normal subjects reported an increase in pleasurable effects when
combining dl-MPH with ethanol [44]. Such positive subjective effects may
predispose individuals to greater abuse liability [32-33, 45]. The enhanced
reward value of this drug combination may be based on interactive effects of
these two psychoactive drugs on excitatory neural systems as recently been
reported using a C57 mouse behavioral model [46]. Further, these increased
effects may also pertain to the elevated rate at which d-MPH reaches the
bloodstream, a temporal aspect associated with abuse potential [47-49].
Thus, when dl-MPH is combined with ethanol, the time to maximum
concentration (Tmax) occurs at the same time as dl-MPH dosed alone,
however, the Cmax has been found to be significantly higher at this time [27].
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Societal/medical Implications of MPH-ethanol Interactions
There is an increasing number of adults being diagnosed with ADHD
and most adult ADHD patients report ethanol use. Previous studies have
shown a significant pharmacokinetic interaction between dl-MPH and ethanol
in humans given therapeutic doses of oral dl-MPH [16, 27]. However, little
work has addressed pharmacokinetic or pharmacodynamic interactions that
may follow after abuse level dosing- bingeing. Further, the introduction of
transdermal dl-MPH is of special concern due to the high levels of circulation
I-MPH which are thought to enantioselectively interact and inhibit CES1. The
interaction with ethanol could significantly alter the therapeutic effects of dlMPH or contribute to side effects.
Therefore, the experiments described in this dissertation were
designed to specifically address the following:
Specific Aim 1. Establish the rewarding properties of dl-MPH as evidenced
by drug seeking behavior in a C57 mouse model.
1A. Determine if C57 mice will self-administer dl-MPH.
1 B. Examine the drug seeking behavior of C57 mice for dl-MPH
following increasingly difficult behavioral demands.

1C. Determine the maintenance of drug seeking behavior following a
two week abstinence of any drug or cue.
Specific Aim 2. Investigate the effects of ethanol on the concentration of dMPH and 1- MPH in the blood, brain and urine of C57 mice.
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2A. Develop new enantiospecific analytical methodology to establish
the dose delivered by transdermal dosing for oral dose selection.
28. Analyze brain, blood and urine concentrations of d-MPH and 1MPH following oral and transdermal dosing applying novel
enantiospecific methodologies.

2C. Analyze micro-samples of brain, blood and urine for concentrations
of d-MPH and 1- MPH following an oral dl-MPH dose that reflects a
comparable transdermal dose.
Specific Aim 3. Investigate stimulant effects of dl-MPH with or without ethanol
on the locomotor activity of C57 mice.
3A. Develop methodology for analyzing locomotor activity of C57 mice
given dl-MPH transdermally compared to oral dosing.
3B. Establish the interactive effects of ethanol and transdermal dlMPH on the locomotor activity of C57 mice.
3C. Examine the interactive effects of ethanol and oral dl-MPH on the
locomotor activity of C57 mice.
The results from these animal investigations will be discussed with a
translational focus regarding the rational individualization of drug selection for
vulnerable adult ADHD patients, i.e., those that consume and/or abuse
ethanol.
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Chapter 2

Reward value of methylphenidate in C57BU6J mice
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Introduction
The stimulant MPH provides a first-line pharmacotherapy for ADHD in
both children and adults. There have been few animal studies modeling the
abuse potential of MPH in the context of its reward properties. The
Spontaneously Hypertensive Rat has been used in efforts to model the
ameliorating effects of MPH on ADHD-like behaviors. While this rat appears
to exhibit drug seeking behavior [50], other lines of evidence reveal that this
particular rat does not model the control of ADHD symptoms by MPH [51-52].
Other studies using the Sprague-Dawley rat show that they also exhibit drug
seeking behavior in response to MPH [53] and the response of this strain to
stimulants of abuse has been well characterized. The current study aims to
characterize the reward value of MPH in a novel mouse model.
Self-administration is an operant conditioning approach that gauges
the reward properties of a particular drug. Typically, the test drug is
administered intravenously. It is a widely utilized and well validated model of
drug addiction liability and abuse potential. Reinstatement of drug seeking
behavior after an extended abstinence period indicates the extent of addiction
liability/reward value of the drug evaluated. Accordingly, we used this
approach in the present study to measure the reward value of MPH in a novel
C57BU6J (C57) mouse model. The C57 mouse strain was chosen based on
its frequent use as a reference strain in preclinical psychopharmacology of
stimulant agents; including MPH [40, 46, 54-55]. Further, C57 mice have
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been shown to self-administer cocaine [56] as well as reinstate cocaine
seeking behavior in response to conditioned stimuli [57]. Cocaine is similar to
MPH in its pharmacodynamic [58] and pharmacokinetic [35] characteristics,
therefore we hypothesize that C57 mice will self-administer MPH and will act
as a useful animal model for ongoing studies of MPH drug abuse
pharmacology.

Materials and Methods
Animals
Experimentally na"ive C57 male mice (n=8, 6-8 weeks old, Jackson
Laboratories) were individually housed in an AALAC accredited animal facility
and were maintained on a 12 h light cycle (lights on at 0600h). Behavioral
testing occurred during the dark phase of their circadian cycle. The mice had
free access to water, and food was restricted to maintain bodyweights at 900/0
of ad libitum weight after the jugular catheterization surgery. All experimental
protocols were approved by the Institutional Animal Care and Use Committee
and were consistent with the guidelines of the NIH Guide for the Care and
Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996).
Catheter Surgery
Mice were anaesthetized using gaseous isofluorane. Chronic
indwelling catheters were designed and constructed for insertion into the right
jugular vein with a skull-mounted access port as previously reported [56, 59].
Catheters were flushed daily with 0.1 mL of antibiotic (Cefazolin) followed by
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0.1 mL of heparin. Mice were given 2 days for postoperative recovery before
experimentation. Catheter patency was tested by injecting 0.1 mL of
thiopental sodium on the day before and the last day of self-administration
testing. Mice that did not lose muscle tone within 2-3 sec were excluded from
the experiment.

Self-administration
Self-administration training was conducted during 2 h sessions on
consecutive days. The self-administration chambers (Med Associates, Inc.,
Georgia, VT, model ENV-307A) were enclosed in sound attenuating cabinets.
Presentation of stimuli and data collection was controlled by MedPC software.
Catheters were connected to liquid swivels via silastic tubing. The swivels
were suspended above the operant conditioning chamber and were
connected to infusion pumps. Two response levers were located 6.5 em
above the grid floor on the same wall of the chamber. A reinforced response
on the active lever resulted in 1) termination of the red house light, 2) initiation
of a 2 sec compound conditioned stimulus consisting of a tone (2,900 Hz,
ENV-323A), a white LED stimuli light (ENV-321 M) located directly above the
active lever, and the infusion pump noise, and 3) infusion of 0.1 mg/kg of
MPH. Mice were first trained to press a lever according to a fixed ratio (FR) 1
schedule of MPH reinforcement with 2 sec time-out period. During the
sessions, responses on the inactive lever had no programmed consequences
but were recorded. Active and inactive lever assignments were randomized.
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Daily self-administration training sessions were continued until the mouse
reached the acquisition criterion (i.e.

~

10 infusions self-administered per

session on a minimum of 5 consecutive training days). After acquisition on an
FR1 schedule, mice were trained on an FR2 schedule using the same criteria
and consequences for lever pressing. Following acquisition on an FR2
schedule, mice were finally trained on a progressive ratio (PR) 2 schedule
using the same criteria and consequences for lever pressing.
Abstinence

Mice were maintained in their home cages for 14 consecutive days
with food and water ad libitum.
Reinstatement testing

The first reinstatement test was conducted on an FR1 schedule, the
second was conducted on an FR2 schedule, and the third was conducted on
a PR2 schedule. During the test sessions, mice were connected to the
silastic tubing previous used to deliver drug and lever presses were recorded
for 2 h on the previously active and inactive levers with the tone and light
consequences, but without any drug delivery.
Cue-less training

Mice were placed in the operant chamber for 2 h sessions for 2 weeks
and there were no programmed consequences for either lever.
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Statistical Methods

Repeated measures analyses of variance (ANOVA) were used to
analyze MPH intake and lever responses. Lever (active vs. inactive) and day
(self-administration, reinstatement, cue-less) were included as repeated
measured factors. Statistical analysis was conducted using SPSS 12.0
(SPSS I.; Chicago, Illinois, USA). Statistically significant interaction effects
were further investigated using Tukey post-hoc tests.
Results
All test animals met training criteria on an FR1 schedule within 10 days
of the initial testing session demonstrating that C57 mice will self-administer
MPH and acquire self-administration quickly as shown by mean lever presses
on the active lever being significantly greater than the inactive lever.
Moreover, self-administration of MPH was maintained despite increasingly
difficult behavioral demands (Figure 2.1).
Following a 2 week abstinence period, lever pressing significantly
increased on both the active and inactive levers during reinstatement training
compared to the final training session at an FR 2 schedule (Figure 2.2).
Further, the ratio of reinstatement over training mean lever presses on the
active lever was significantly greater showing an increase in reward value
through drug seeing behavior.
Removing the light and tone cues attenuated mean lever presses on
both the active and inactive levers, but did not completely eliminate drug
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seeking behavior implying that the drug seeking behavior is not simply a
response to conditioned cues (Figure 2.3). Drug seeking behavior was
significantly decreased during a cue-less testing session compared to a
reinstatement testing session on an FR2 schedule.
Discussion
Previous studies using the spontaneously hypertensive rat as a model
for ADHD show that they do exhibit drug seeking behavior [50]. However,
growing evidence suggests that this rat is quite limited as an appropriate
model for ADHD, particularly in their response to first-line therapeutic agent
MPH [51-52]. The C57 mouse is a widely used reference strain for drugs of
abuse [40-41 , 46, 55]. C57 mice have been shown to self-administer cocaine
[56] and in the present study have been shown to quickly acquire drug
seeking behavior of MPH. Further, self-administration was maintained despite
increasingly difficult demands. The special reward value of MPH is revealed
through the robust drug-seeking behavior recorded, despite a two week
abstinence period and the lack of drug reinforcement. In addition, we have
demonstrated the maintenance of drug seeking behavior despite removal of
condition cues which implies that the drug seeking behavior in this study was
not based on a conditioned response, but rather due to the reward value of
MPH itself. Our findings add support for the use of C57 mice as an
appropriate reference stain and species to characterize MPH
neuropharmacology in translational research.
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Figure Legends
Figure 2.1
Mean lever presses on the active lever were significantly greater than the
inactive lever on days 5-20. (all p>O.001)
Figure 2.2
Mean lever presses on both the active and inactive levers were significantly
increased (*p<O.001) during reinstatement testing following a two week
abstinence period.
Figure 2.3
Mean lever responses on both the active and inactive levers significantly
decreased when the conditioned stimuli were removed, but were not
completely eliminated. (*p>O.001).
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Chapter 3

Transdermal and oral dl-MPH - ethanol interactions in C57BU6J mice:

Transesterification to ethylphenidate and elevation of d-MPH
concentrations
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Introduction
ADHD is the most commonly diagnosed childhood neuropsychiatric
condition. The stimulant drug dl-MPH has remained a first-line
pharmacotherapeutic agent to treat ADHD since the 1950s [3, 15-16].
Further, the persistence of ADHD into adulthood is increasingly recognized
[1-6]. In the adult ADHD population, dl-MPH is also the most widely
prescribed psychotherapeutic agent [5]. As a consequence, this controlled
substance has become more widely available for abuse and diversion [17-19],
especially among high school [20] and college students [21-22].
Appropriate drug therapy for this older ADHD population requires a
special consideration of lifestyle and lifespan comorbidities [5], such as
hypertension [21, 23]. Optimized adult ADHD pharmacotherapy may be
complicated by alcohol consumption, alcohol use disorder (AUD) or other
substance use disorders (SUD). Both AUD and SUD are over-represented in
adult ADHD [1, 30-31], especially in women [60]. Not surprisingly, given the
clinical nature of adult ADHD [61], and the susceptible population for which
MPH is prescribed [1], dl-MPH related emergency department visits have
numbered in the thousands each year, e.g., 8,000 for 2004 [19]. Moreover,
emergency room presentations for incidents involving alcohol in combination
with drugs have risen 63% for persons aged 18 to 19 years, and have
increased 100% for persons age 45-54 [62]. Poison center data reveal how
extensive dl-MPH abuse has become [19, 63-66]. In a drug diversion context,
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ADHD stimulants are often co-abused with ethanol, e.g., in 53% of those
surveyed [67]; and dl-MPH in particular has been reported to be co-abused
with ethanol in 92% of those surveyed [18]. Accordingly, prescribing or
diverting psychostimulants has generated special concern regarding
concomitant ethanol use or abuse [32-34].
These statistics are consistent with MPH being classified as a DEA
schedule II controlled substance [68], i.e., a medication of very high abuse
potential [44, 69-70]. Accordingly, the prevalence and inherent danger of
concomitant dl-MPH and ethanol warrant research into the pharmacology of
this drug combination.
Coadministration of ethanol and dl-MPH orally to humans [27, 36]
results in a drug - drug interaction where the methyl ester of MPH is
transesterified to yield ethylphenidate (EPH; Figure 3.1) [27] in addition to
being hydrolyzed to the inactive [24] metabolite ritalinic acid [25]. Both EPH
and ritalinic acid formation appear to be primarily mediated by the actions of
carboxylesterase 1 (CES1) [37-39] which exhibits I-MPH substrate
enantioselectivity in both the transesterification and hydrolysis pathways [27,
40).
The metabolic transesterification of dl-MPH with ethanol to yield EPH
was first reported in vitro using rat microsomes [71]. Subsequently, EPH was
detected in human tissues from two fatal drug overdoses in which unknown
amounts of MPH and ethanol were consumed [72]. These findings prompted
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a normal human volunteer pilot study of the dl-MPH - ethanol interaction [73],
followed by a larger human study where enantiospecific methodology for
plasma analysis was utilized [44]. In this latter study, it was established that
the dl-MPH - ethanol transesterification pathway primarily yields the 1enantiomer of EPH (Figure 3.1).
Any I-MPH, or the metabolite I-EPH, which reaches the bloodstream is
unlikely to contribute directly to the pharmacodynamics of the dl-MPH ethanol interaction in view of the findings that only the d-isomers of MPH and
EPH possess potent effects on dopaminergic and noradrenergic systems [4041]. This notwithstanding, ethanol consumed with dl-MPH by normal human
volunteers resulted in a significant elevation of maximum plasma d-MPH
concentrations (Cmax) and overall d-MPH exposure [27]. Elevated plasma dMPH concentrations increase the potential for adverse cardiovascular events,
especially in ADHD patients with comorbid hypertension [42-43].
In addition to the influence of ethanol on dl-MPH pharmacokinetics, the
above normal subjects reported an increase in pleasurable effects when
combining dl-MPH with ethanol [44]. Such positive subjective effects may
predispose individuals to greater abuse liability [32-33, 45]. The enhanced
likability of this drug combination may be based on interactive effects of these
two psychoactive drugs on excitatory neural systems as recently reported
using a C57BUJ6 (C57) mouse behavioral model [46]. However, the
increased likability may also pertain to the elevated rate at which d-MPH
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reaches the bloodstream [47-49]. When dl-MPH is combined with ethanol, the
time to maximum concentration (Tmax) occurs at the same time as dl-MPH
dosed alone. However, the C max is much higher at this time following
concomitant dl-MPH and ethanol than when dl-MPH is dosed alone [27].
In 2006, the FDA approved the first transdermal patch for the
administration of dl-MPH (Daytrana~. This dl-MPH transdermal delivery
system (MTS) relies on a high load of dl-MPH free base incorporated within a
uniform blend of acrylic polymers and silicone adhesives to drive drug
absorption based on the drug concentration gradient, without the need for
permeability enhancers (for review see [16]). Using transdermal delivery of dlMPH circumvents the extensive and highly enantioselective presystemic
metabolism associated with oral dosing [27-28]. Accordingly, MTS results in
approximately 50 times higher plasma I-MPH concentrations than occur
following oral dosing [29].
The present preclinical study investigated aspects of MTS and oral
MPH absorption and disposition as influenced by the coadministration of
ethanol. Special attention was given to the formation of I-EPH in view of the
relatively large amount of I-MPH anticipated to reach the bloodstream
following MTS delivery. The C57 mouse strain was chosen based on its
frequent use as a reference strain in preclinical psychopharmacology of
stimulant agents; including MPH and ethanol [40-41,46, 55,74]. Further, like
human MPH metabolism, the C57 mouse has previously been reported to
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favor I-MPH as a substrate in the transesterification of ethanol to yield I-EPH
after intraperitoneal (Lp.) dosing [40].
Blood, brain and urine concentrations of d-MPH, I-MPH, d-EPH and 1EPH were analyzed. The mean MTS dose delivered from a % of a 12.5 cm 2
patch (smallest of 4 sizes available) after a 3.25 h wear was calculated by
quantifying the residual MPH content in the used patches. This dose was then
administered for oral studies, while clearly recognizing the limitations of any
direct drug dispositional comparisons of a bolus oral dl-MPH dose to that of
the MTS in mice where prolonged release of drug occurs from the patch. A
modification of an established gas chromatographic-mass spectrometricelectron impact-selected ion monitoring (GC-MS-EI-SIM) method was used
for these enantiospecific determinations [41, 75]. MPH and EPH enantiomers
were derivatized with (S)-N-trifluoroacetylprolyl chloride (TFP-CI) to yield GC
resolvable diastereomers. Piperidine-deuterated dl-MPH was incorporated for
analytical control.

Materials and Methods
Materials
Ethanol used for oral animal studies was from AAPER Alcohol and
Chemical Co. (Shelbyville, KY; 950/0). dl-MPH·HCI used for oral animal
studies was from Sigma-Aldrich (St. Louis, MO; lot # 118K1052) and the 12.5
cm 2 size MTS was from Shire US CVVayne, PA; lot # 2616811; smallest of 4
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sizes available). Laboratory tape used to secure MTS or placebo was from
WlR International (white, 12.7 mm). dl-MPH·HCI in methanol (1 mg/mL
calculated as free base; Cerilliant, Round Rock, TX) was used as the
analytical reference standard. The dl-EPH·HCI standard in ethanol (1 mg/mL
calculated as free base) was synthesized in-house[41]. (S)-N(trifluoroacetyl)prolyl choride in dichloromethane (1 M; Aldrich-Aldrich), sodium
carbonate (Fischer Scientific, Fair Lawn, NJ), n-butyl chloride (Burdick &
Jackson, Muskegon, MI) and acetonitrile (Mallinckrodt Inc, Paris, KT) were
used. Piperidine deuterated dl-MPH·HCI was synthesized in-house[76] and
contained approximately 25% of the Ds-isotopolog for SIM monitoring and
containing no Do-1-MPH. It is noted that piperidine deuterated Dg-MPH·HCI is
commercially available (Cerilliant).
Animals

Male C57 mice aged 8-10 weeks (25-35 g) were obtained from
Jackson Laboratories (Bar Harbor, Maine, USA). They were individually
housed in a temperature and humidity controlled colony room on a 12-h
light/dark cycle (light: 07.00--19.00 h) with free access to food and water for at
least 7 days before the start of any tests. All experiments were approved by
and conducted within the guidelines of the Institutional Animal Care and Use
Committee at the Medical University of South Carolina and followed the
guidelines of the NIH Guide for the Care and Use of Laboratory Animals (NIH
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Publication no. 80-23, revised 1996). Animal studies were conducted in the
Institute of Psychiatry.
Drug Administration
Mice were randomly placed into 1 of 4 test groups as shown in Table
1. All mice, regardless of group assignment, were treated similarly. This
included the use of active (MTS) or placebo patches and delivery of ethanol
or water by gastric intubation (gavage). To this end, mice were lightly
anesthetized by placement into a chamber containing 5% isofluorane for 8-10
min. The mice were removed and their hair was clipped along their abdomen
and back, from shoulders to hips.
Immediately after clipping hair, % of a 12.5 cm 2 MPH transdermal patch,
or a placebo patch (band-aid adhesive resembling the MTS), was applied to
the lower left hip area. The patch was secured by applying tape over the
patch and around the mouse for one full loop in order to ensure a constant
skin interface and to prevent the mice from disturbing the patch. Mice were
returned to their home cage for 15 min to recover from anesthesia, then
dosed by gavage, according to their assigned group, i.e., 3.0 g/kg ethanol and
7.5 mg/kg (calculated as the free base) dl-MPH·HCI, or deionized water
(dH 2 0) using a standard volume of 0.02 mUg body weight.
Sample collection
Following gavage, mice were individually placed for 3 h in single
metabolic chambers designed to separate urine from solid waste. Urine was
collected and measured to the nearest f,.IL. Mice were then deeply
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anesthetized using isofluorane. Venous blood was collected using cardiac
puncture and stored in heparinized tubes. The brain was removed, separated
along the sagittal line, weighed, and stored as 2 separate samples. Used
patches were collected and later extracted for residual dl-MPH to calculate
the dose delivered to the cutaneous site. Blank urine, blood, and brain used
for calibration curves were collected from mice not exposed to any drugs. All
matrices were kept on dry ice until stored in a -70°C freezer.

Sample Preparation
Urine
All urine samples were thawed immediately prior to analysis. Blank
mouse urine (150 IJL) was fortified with dl-MPH over a range of
concentrations (0, 0.5, 0.75, 1.5, 3,4.5 IJg/mL) and dl-EPH (0, 0.15, 0.3, 0.45,
0.6, 0.9 1J9/mL) (Figure 3.4). These calibrators were run in parallel with
experimental urine samples (150 IJL). The internal standard, piperidine
deuterated dl-MPH, was dissolved in dH 2 0 such that 200 IJL aliquots provided
a concentration of 5 1J9 D s-dl-MPH/1S0 IJL of urine. Sodium carbonate (SO IJL;
1.2 M) was added to each urine sample to adjust the pH to approximately 9.5.
Samples were extracted with n-butyl chloride: acetonitrile (2 mL; 4: 1) by
vortexing for approximately O.S min.
Blood
All blood samples were thawed immediately prior to analysis and used
in the freezer- hemolyzed state in view of MPH having previously been
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reported to distribute nearly equally between serum and the red cell fraction
[77]. Blank mouse blood (200 IJL) was fortified with dl-MPH over a range of
concentrations (0, 0.05, 0.1, 0.25, 0.5, 0.75, 1.0 IJg/mL) and with dl-EPH (0,
0.01, 0.025, 0.05, 0.075, 0.1 J..Ig/mL). These were run in parallel with
experimental blood (200 IJL) as calibrators. The internal standard, piperidine
deuterated dl-MPH, was dissolved in dH 20 such that 200 J,JL aliquots provided
a concentration of 5 IJg D5-dl-MPH/200 J..IL of blood. Sodium carbonate (2mL;
1.2 M) was added to each blood sample to adjust the pH to approximately
9.5. Samples were extracted with n-butyl chloride: acetonitrile (2 mL; 4:1) by
vortexing for approximately 0.5 min.

Brain
All brain samples were thawed immediately prior to analysis. Blank
mouse brain (1/2, left hemisphere) was fortified with dl-MPH over a range of
concentrations (0, 0.025, 0.05, 0.1, 0.2, 0.5, 1.0, 1.5 tJg/g) and with dl-EPH (0,
0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1.0 J..Ig/g) and run in parallel with experimental
brains (left hemisphere). The internal standard, piperidine deuterated dl-MPH,
was dissolved in dH 2 0 such that 200 JJL aliquots provided a concentration of 5
J..I9 D5-dl-MPH/150 J..IL of urine. The internal standard, piperidine deuterated dlMPH, was dissolved in dH20 such that 200 J..IL aliquots provided a
concentration of 2.5 J,Jg D5-dl-MPHI brain sample. Sodium carbonate (2mL;
1.2 M) was added to each brain sample to adjust the pH to approximately 9.5.
Samples were homogenized (Polytron PT1200) for 10 sec, then 0.5 9 sodium
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chloride was added and the samples were vortexed for 20 sec. Samples were
extracted with n-butyl chloride: acetonitrile (2 mL; 4: 1) by vortexing for 30 sec,
then centrifuged at 3000 rpm for 7 min.

MPH extraction from used patches
Used patches were analyzed for residual content of dl-MPH to
establish the cutaneous dose delivered. Before being placed on the animal,
whole patches (including the backing) were weighed and then cut into
quarters. Each % was then weighed and used to determine what percent of
the whole patch it represented.
In advance of analyzing the used patches for their dl-MPH content, a
method for

dl-MPH recovery from unused patches was developed. The

unused patches were placed in scintillation vials with methanol (1
mL/calculated mg of dl-MPH) and sonicated over a range of times from 1 min
to more than 20 min to determine the time required for near complete
extraction/recovery. An unused 12.5 cm 2 patch contains 27.5 mg of dl-MPH
free base whereby a % patch contains 6.875 mg of dl-MPH. For specific %
patch cuttings, the exact dl-MPH content was calculated as follows: (Weight
of % MTS / Weight of whole MTS) x 27.5 = mg dl-MPH. Accordingly, for the
used study patches, residual

dl-MPH was determined by taking a 100

aliquot after 15 min of sonication and adding D5-dl-MPH (10 (..Ig) as the
internal standard.
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Chiral derivatization
The organic phases from all matrix extractions were transferred into 4
mL screw-cap silanized vials (Supelco) and the solvent was evaporated to
dryness under nitrogen. TFP-CI (1 M; 250 IJL) was added to each vial, sealed
with Teflon® lined caps (Supelco) and heated at 58°C for 45 min. Aliquots of
these samples were then transferred to silanized microvial inserts within auto
sampler vials for GC-MS analysis.
Instrumental analysis
All analyses were conducted using an Agilent Model 6890 GC-5973N
MS with ChemStation using a modification of published methods [41, 75]. GC
separations were on a 30 m x 0.32 mm, 0.25 J..lm film thickness, 5%
phenylmethylpolysiloxane fused-silica column (D8-5 J & W Scientific, Folsom,
CA). Pulsed-splitless injections (2 JJL) were used. The injector port was fit with
a deactivated glass wool protected sleeve operated at 250°C and the helium
carrier gas linear velocity was 50 cm/s. The GC was held at 70° C for 1.5 min,
then ramped to 315°C at 10° C/min and held for 4 min for a total run time of
30 min. Detection was by EI ionization (70 eV) and SIM, acquiring the N-TFPpiperidyl fragment ions of d-MPH, I-MPH, d-EPH and I-EPH (m/z 277) with D5d-MPH and D5-I-MPH monitored at m/z 282 (Figure 3.2).
The lower limit of quantitation was based on a signal-to-noise ratio of
~1 0

~

for all analytes. The signal-to-noise ratios for the lowest calibrators were

25. It is noted that calibrator concentrations are indicated as racemic (dl-)
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MPH and EPH, while analyte concentrations are reported for each
enantiomer. All calibration plots provided linearity of f2 > 0.99 (Figure 3.3).

Statistical Methods
A two way analysis of variance (ANOVA) followed by pair wise
comparisons using the Student's t-test method was used in the analysis of all
data. Samples were analyzed as independent samples and were assumed to
have equal variances. Statistical analysis was conducted using SPSS 12.0
(SPSS I.; Chicago, Illinois, USA).

Results
MPH dose delivered from MTS
The dl-MPH dose received by the MTS test animals over the 3.25 h
wear time was determined by extracting the remaining dl-MPH from used
patches and back calculating from the initial dl-MPH content in a % of a 12.5
cm 2 MTS (Figure 3.4). Sonication for 15 min was necessary to extract a
mean no less than 95% of the labeled dl-MPH content of unused % patches
and, accordingly, 15 min of sonication was used to calculate the 3.25 h dose
delivered by difference (Figure 3.5). Shorter sonication times did not allow for
complete dl-MPH extraction, while using later time points caused the MTS
matrix to significantly degrade. This resulted in the extractant becoming
cloudy and GC-MS of such aliquots were found to foul the injector port and
result in unacceptable chemical noise in the chromatograms. The mean dl-
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MPH dose delivered using the MTS over 3.25 h was 0.23 mg or 7.5 mg/kg.
This dose was used for oral dosing (gastric intubation) in a parallel study of
oral dl-MPH - ethanol interactions. The 7.5 mg/kg oral dose is likely to overrepresent the bioavailable fraction of the mean dl-MPH MTS dose calculated
as above in view of the likelihood of some residual dl-MPH remaining in the
skin prior to circulatory absorption, e.g., in humans dosed with MTS, residual
dl-MPH results in a biphasic decay of the drug from plasma following patch
removal [78].

Influence of ethanol on urinary analytes
Transdermal dl-MPH
The total urinary elimination of d-MPH following the 3.25 h MTS wear
time was significantly greater in the animals dosed with ethanol compared to
those given dH20 (Figure 3.6a; t

= 5.52, df = 10, p<0.001); rising from 0.48 IJg

to 1.39 1-19 to account for 0.04% of the total dose of d-MPH calculated to be
cutaneously delivered. Further, in animals dosed with MTS, total urinary
excretion of I-MPH was significantly increased, rising from 0.43 1-19 for animals
dosed with dH 20 to 0.96 JJg for animals dosed with ethanol (Figure 3.7a; t

=

4.07, df = 10, p<0.01). There was not a significant difference between the
urinary excretion of d-MPH compared to I-MPH in animals dosed with dH20,
however, in animals dosed with ethanol the urinary excretion of d-MPH was
significantly greater than I-MPH (t

=2.13, df = 10, p<0.05). Both enantiomers

of EPH were detectable in animals gavaged with ethanol, however, I-EPH
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was enantioselectively formed with a significantly greater total elimination
found relative to d-EPH (Figure 3.8a; t = 5.74, df = 10, p<0.001). The total
urinary elimination of I-EPH was 0.2

~g

which represents 0.01 % of the total

dose of I-MPH calculated to be cutaneously delivered, while the total urinary
elimination of d-EPH was 0.05

~g.

The total urine volume excreted following

ethanol treatment was significantly greater than following dH20 treatment (t =
4.81, df = 10, p<0.001) as consistent with the diuretic effect of ethanol.

Oraldl-MPH
The total urinary elimination of d-MPH following oral dl-MPH over the 3
h collection period was significantly greater in the animals dosed with ethanol
compared to those given dH 2 0 (Figure 3.6b; t = 7.56, df=10, p<0.001); rising
from 0.09

~g

to 0.46 J,Jg and accounting for 0.0120/0 of the total dose of d-MPH

gavaged. Further, in animals dosed with oral dl-MPH, the total urinary
excretion of I-MPH was significantly increased, rising from 0.071-19 for animals
dosed with dH 2 0 to 0.31 ~g for animals dosed with ethanol (Figure 3.7b; t =
5.45, df= 10, p<0.001). There was not a significant difference between the
urinary excretion of d-MPH compared to I-MPH in animals dosed with dH 20,
however, in animals dosed with ethanol the urinary excretion of d-MPH was,
significantly greater than I-MPH (t = 2.23, df = 10, p<0.05). Both isomers of
EPH were detectable in animals gavaged with ethanol, however, I-EPH was
enantioselectively formed with a significantly greater total urinary elimination
of /-EPH relative to d-EPH (Figure 3.8b; t = 3.71, df = 10, p<O.01). The total
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urinary elimination of /-EPH was 0.02 IJg, while the total urinary elimination of
d-EPH was 0.005JJg. Again, the total urine volume excreted followed ethanol
(a diuretic) treatment was significantly greater than following dH 2 0 treatment (t
= 4.39, df

= 10, p<0.001).

Influence of ethanol on blood analytes
Transdermal dl-MPH
The blood concentration of d-MPH after MTS dosing was significantly
greater in animals dosed with ethanol compared with dH 2 0; increasing 72%
from 0.36 JJg/mL to 0.61 IJg/mL (Figure 3.6a; t = 4.22, df = 10, p<0.01 ),.
Further, in animals dosed with MTS, concentrations of I-MPH significantly
increased from 0.29 J,J9/mL for animals dosed with dH20 to 0.51 J,Jg/mL for
animals dosed with ethanol (Figure 3.7a; t = 2.82, df = 10, p<0.05). There was
no significant difference between the blood concentration of d-MPH and 1MPH in animals dosed with dH 2 0 or in animals dosed with ethanol. Both
enantiomers of EPH were formed in animals gavaged with ethanol, however,
I-EPH was enantioselectively formed with a significantly greater concentration
found relative to d-EPH (Figure 3.8a; t

=2.99, df = 10, p<0.05). The blood

concentration of I-EPH was 0.04 IJg/mL, while the concentration of d-EPH
was 0.03 J,Jg/mL.
Oraldl-MPH
The blood concentration of d...MPH following oral dl-MPH was
significantly greater in the animals dosed with ethanol compared to those
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given dH 2 0; increasing 59% from 0.018 IJg/mL to 0.03 IJg/mL (Figure 3.6b; t =
2.95, df = 10, p<0.05). Further, in animals dosed with oral dl-MPH,
concentrations of I-MPH were significantly increased from 0.015 1J9/mL for
animals dosed with dH 2 0 to 0.05 IJg/mL for animals dosed with ethanol
(Figure 3.7b; t = 4.56, df = 10, p<0.001). There were no significant differences
between the blood concentration of d-MPH and I-MPH in animals dosed with
dH 2 0 or in animals dosed with ethanol. Neither isomer of EPH was detectable
in animals gavaged with oral dl-MPH and ethanol.

Effect of ethanol on brain analytes
Transdermal dl-MPH
The brain concentration of d-MPH after MTS dosing was significantly
greater in animals dosed with ethanol compared the dH20 group; increasing
65.3%from 0.81 1J9/9 to 1.34 IJg/g (Figure 3.6a; t = 2.89, df =10, p<O.05).
Further, in animals dosed with MTS, concentrations of I-MPH were
significantly increased by ethanol, rising from 0.84 1J9/9 for animals dosed
with dH 2 0 to 1.33 1J9/g for animals dosed with ethanol (Figure 3.7a; t = 2.18,
df =10, p<O.05). There were no significant differences between the brain
concentration of d-MPH and I-MPH in animals dosed with dH20, or in animals
dosed with ethanol. Both isomers of EPH were formed in animals gavaged
with ethanol, however, I-EPH was enantioselectively formed with a
significantly greater concentration found relative to d-EPH (Figure 3.8a; t =
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8.57, df

= 10, p<O.001). The brain concentration of I-EPH was 0.14 J.J9/g,

while that of d-EPH was 0.005 IJg/g.

Oraldl-MPH
The brain concentration of d-MPH following oral dl-MPH was
significantly greater in the animals dosed with ethanol compared to those
given dH20; increasing 40.60/0 from 0.03 J.Jg/g to 0.05 J.Jg/g (Figure 3.6b; t =
3.67, df

= 10, p<0.01). Further, in animals dosed with oral dl-MPH,

concentrations of I-MPH were significantly increased from 0.02 IJg/g for
animals dosed with dH 2 0 to 0.06 J.j9/9 for animals dosed with ethanol (Figure
3.7b; t

=3.83, df = 10, p<0.01). There were no significant differences between

the brain concentration of d-MPH and I-MPH in animals dosed with dH20 or in
animals dosed with ·ethanol. Both isomers of EPH were formed in animals
gavaged with ethanol; however, I-EPH appeared to have been
enantioselectively formed, though the mean concentration was not
significantly different from that of d-EPH (Figure 3.8b).

Discussion

Oral dl-MPH in humans is subject to pronounced enantioselective firstpass metabolism which limits I-isomer systemic exposure to approximately
1% that of d-MPH [28]. The mean absolute bioavailability of dl-MPH has been
reported to be 300/0, but ranges from 11-51 % [79-80]. In effect, first-pass
metabolism biocatalytically "resolves" oral dl-MPH [81], resulting in only the d-
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isomer appreciably reaching the bloodstream. The d-isomer component of dlMPH is generally regarded as the pharmacologically active isomer,
responsible for efficacy in the treatment of ADHD [82-83]. The low oral
bioavailability of dl-MPH is largely due to the facile hydrolysis of the
constituent methyl ester to yield the inactive [24] metabolite dl-ritalinic acid
and catalyzed primarily through the actions of CES1 [37-39, 84]. This facile
pathway limits the half-life of dl-MPH to only 2-3 h [85]. Approximately 1% of
MPH is excreted in urine unchanged in humans over 24 h, and excreted
predominantly as the d-isomer [75].
Our studies with mice dosed with oral dl-MPH (7.5 mg/kg) and dH20,
while being limited to a single 3 h time point for blood and brain sampling,
suggest a lower degree of metabolic enantioselectivity relative to humans.
whereby the d-MPH-to-I-MPH ratio for blood and brain were 1.22 and 1.36,
respectively. This apparent greater oral bioavailability of I-MPH in the C57
mouse than in man is in general agreement with plasma results using CD1
mice dosed at 5.0 mg/kg [86] or pregnant rats dosed at 7.0 mg/kg [87] .
Further, the extent of accumulation in brain relative to blood will be expected
to be less dramatic at 3 h than at earlier time points, especially after oral
administration were the decay time course to resemble that of the SpragueDawley rat [77].
A primary aim of the present study was to model transdermal MPH ethanol metabolic interactions. A quarter of the smallest commercially
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available MTS patch was used and this delivered a mean dose of
approximately 7.5 mg/kg of dl-MPH over the 3.25 h wear period based on the
difference between drug content before and after application. Though the
MTS is not designed to be cut into portions for clinical applications, the

dl-

MPH content in each patch is evenly distributed throughout the patch [16] and
required apportioning when using such a small species as the mouse. dl-MPH
delivery has been reported to occur in a manner directly proportional to the
patch surface area in humans [16, 88]. Accordingly, the drug content in the %
12.5cm2 patches used in the present study was 250/0 of 27.5 mg, i.e., 6.88
mg. The mean dose of 0.23 mg of dl-MPH delivered to the mice (n = 12) over
the 3.25 h wear represents 3.3% of the % patch content of dl-MPH and
ranged from 1.9 - 5.1 %. In humans, the uncut 12.5 cm 2 patch size is designed
to deliver a mean dl-MPH dose of 10 mg over the recommended 9 h wear.
This dose represents 36% of the patch dl-MPH content, though ranging
between subjects from 15-72% [89].
These apparent transdermal dl-MPH absorption differences reflect
many factors including: (1) the shorter wear time of 3.25 h for the mouse, (2)
the faster rate of ester substrate metabolism expected with rodents relative to
humans [90], (3) the hair follicle rich shaved skin of the mice opposed to the
skin surface of the recommended hip placement in clinical applications, and
(4) the potential for a greater relative absorption lag time for the 3.25 h wear
versus 9 h in humans. In this latter context, the average lag time for
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detectable d-MPH in plasma after applying MTS to humans is 3.1 h (ranging
from 1-6 h) [91]. The above factors notwithstanding, it is recognized that the
percutaneous absorption rate for a range of drugs in mice and other rodents
has generally been found to be more rapid than in humans or pigs [92].
While the present investigation appears to represent the first MTS
study to use mice, previous preclinical studies have shown that shaved mice
serve to model transdermal drug delivery [93]. Hairless or nude mice are
more typically used for transdermal delivery studies across the range of patch
technologies [94], however, the neuropharmacological reference strain status
of the C57 mouse provided the justification for its use in investigating dl-MPH
- ethanol interactions (see Introduction). Maintaining the mice in the
metabolic chambers for a total of 3 h allowed for the collection of adequate
urine volume for analysis, while still permitting quantification of analytes from
blood and brain. In this context, the mean elimination half-life of dl-MPH in
mice (B6C3F1 strain; 3 mg/kg p.o.) has been reported to be 1.1 h [95], while
that of ethanol (2 g/kg i.p.) in C57 mice appears to be approximately 1.3 h

[96].
Enantiose/ective I-EPH transesterification
As with oral dosing in humans [27], coadministration of ethanol and
transdermal or oral dl-MPH in C57 mice resulted in the enantioselective
transesterification of dl-MPH, favoring I-MPH over d-MPH as a substrate.
EPH was detectable in the brain, blood and urine of these mice. Selection of

43

an appropriate species to model esterase-mediated metabolism of dl-MPH
was an important consideration in our study design. For instance, beagle
dogs have been used in pioneering dl-MPH metabolism studies [97], and in
subsequent toxicokinetic studies [98]. However, esterase-mediated hydrolysis
of dl-MPH in beagle dogs exhibit the opposite enantioselectivity, preferentially
deesterifying d-MPH over I-MPH [99]. Further, based on both human
investigations [27], and the present findings with C57 mice, the
enantioselective formation of I-EPH with co-administration of dl-MPH and
ethanol is accompanied by an elevation in d-MPH concentrations relative to
dosing with dl-MPH alone. While I-EPH formation was found to be
enantioselective, this metabolic pathway was not enantiospecific, i.e., I-EPH
concentrations significantly exceededd-EPH values though d-EPH was
readily detectable and quantifiable in C57 mouse samples following MTS and
ethanol, as well as in the urine of animals dosed orally with dl-MPH. In
humans dosed orally with dl-MPH and ethanol, d-EPH rarely exceeded 100/0
of the concentration of I-EPH [27].
In potential forensic medicine applications [72], detection of EPH from
biological samples could serve as a biomarker to demonstrate combined
consumption of dl-MPH and ethanol; analogous to the detection of
cocaethylene as evidence of cocaine - ethanol coabuse [100].
The high degree of hepatic localization of CES1 compared to its low
level of intestinal expression implicates hepatic transesterification as the
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primary site of EPH formation after oral dosing of dl-MPH [38]. However,
when dosing dl-MPH by the transdermal route, presystemic esterase
metabolism may also occur, as has been reported during percutaneous
disposition of ester containing drugs. Transdermal presystemic hydrolysis has
been especially associated with the cutaneous fat layer, where methyl ester
and ethyl ester containing drugs are reported to be readily deesterified in skin
during transdermal transport [92,101-104]. Some degree of presystemic
transesterification of dl-MPH to EPH may also occur. In the presence of
ethanol, transesterification of methyl esters to ethyl esters has been reported
in skin [105]. For instance, the methyl ester methylparaben is rapidly
hydrolyzed in skin [102], though in the presence of ethanol hydrolysis of
methylparaben is inhibited by competitive esterase-mediated
transesterification of methylparaben to ethylparaben in pig [106] or human
[107] skin.
As with hepatic esterase substrates, skin esterase activity has also
been reported to exhibit enantioselectively, e.g., during prodrug ester
activation by hydrolysis [108]. The possibility of cutaneous esterase-mediated
biotransformation resulting in transesterification of transdermal dl-MPH with
ethanol may be favored by the mildly basic cutaneous pH expected at the
MTS application site considering the high concentration of dl-MPH free base
found in MTS [16]. Mild cutaneous basicity has been reported to accelerate
the rate of ester xenobiotic hydrolysis. For instance, esterase activity toward
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transdermal drug substrates was accelerated at a pH of 8, but was inhibited
at the lower pH of 5 [107]. dl-MPH is an especially weak organic base even
though it contains a secondary aliphatic amine; it exhibits a pKa of 8.4 versus
the pKa of 9.6 for the stimulant methamphetamine [109]. This relatively low
basicity of dl-MPH has been theorized to be a consequence of an
intramolecular hydrogen bonding interaction between the amine and the
methyl ester carbonyl within the MPH structure [110].
Still considering the potential for some degree of cutaneous EPH
formation, in addition to subsequent hepatic metabolism, oral ethanol is
rapidly distributed throughout mammalian tissue, and a portion of the nonmetabolized dose is excreted cutaneously (sweat), in addition to ethanol
excretion by the lungs and kidney [111]. Finally, even oral MPH reaches skin,
as demonstrated using commercial sweat patches placed on the back [112].
Significant increases in d-MPH concentrations by ethanol
The concentrations of d-MPH in blood, brain and urine were
significantly greater in mice dosed with ethanol than those dosed with dH 20.
These findings occurred when dosing either transdermally or orally. d-MPH
elevation following concomitant MPH-ethanol administration was especially
pronounced under the conditions used when dosing dl-MPH by the
transdermal route. However, any direct comparisons between the extent to
which ethanol influences either d-MPH concentrations or EPH formation as a
function of dosing route cannot be reasonably made due to the inherent
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disparities of comparing an oral bolus dose of dl-MPH with that of the ongoing
release of dl-MPH from the MTS. It is possible that the elevated I-MPH levels
associated with transdermal dosing in C57 mice relative to oral dosing could
be relevant to the extent to which ethanol elevates d-MPH in the course of
ethanol interacting with CES1 to form I-EPH.
Approximately 50 times more of I-MPH reaches the systemic
circulation in humans when dl-MPH is dosed transdermally than when dosed
orally [29], and I-MPH is the isomer which enantioselectively serves as a
CES1 substrate in the presence of ethanol [27, 38-39, 113-114]. Were
ethanol to facilitate d-MPH absorption from the MTS through esterase
,inhibition at the level of the skin and/or liver, the resulting higher drug
concentrations, and potentially more rapid rate of absorption of MPH, may
influence pleasurable effects [27] of this drug combination, and contribute to
additional abuse liability [47-49]. Further, elevated d-MPH plasma
concentrations pose the potential for adverse or lethal [72] cardiovascular
effects [42-43]. In view of the significant influence of ethanol on d-MPH
concentrations in the C57 mouse model reported here, transdermal dl-MPH
used to treat adult ADHD may be associated with clinical considerations
unique to this route of administration, should drug interaction findings from of
this animal model hold for humans.
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Figure Legends
Figure 3.1
Enantioselective transesterification of dl-MPH to I-EPH following concomitant
ethanol.
Figure 3.2
Representative GC-MS-SIM chromatogram of d-MPH, I-MPH and I-EPH from
a C57 mouse brain extract (upper ion profile). The sample was collected 3.25
h after dosing with % of a 12.5 cm 2 MTS and 3 h after dosing with 3.0 g/kg
ethanol by gavage. Enantiospecific analysis used chiral derivatization and a
deuterated internal standard (lower ion profile).
Figure 3.3
Calibration plots of spiked mouse urine were used to determine
concentrations of MPH and EPH in experimental samples. AliI> 0.99.
Figure 3.4
Residual MPH from used X 12 cm 2 patches established transdermal dose
delivered.
Figure 3.5
Extraction efficiency of unused % 12 cm 2 dl-MPH transdermal patches.
Figure 3.6
(A) In mice treated with X of a 12.5 cm 2 MTS for 3.25 h, ethanol (3.0 g/kg,
gavaged at 0.25 h) increased total excretion of d-MPH in urine and increased
d-MPH concentrations in blood and brain relative to dH 2 0.
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(8) In mice gavaged with dl-MPH (7.5 mg/kg), concomitant ethanol (3.0 g/kg)
increased total 3 h urinary excretion of d-MPH, and increased 3 hd-MPH
concentrations in blood and brain, relative to gavage dosing with dl-MPH (7.5

mg/kg) and dH 2 0. *, P < 0.05; **, P < 0.01; ***, p < 0.001.
Figure 3.7
(A) In mice treated with % of a 12.5 cm 2 MTS for 3.25 h, ethanol (3.0 g/kg,
gavage at 0.25 h) increased total excretion of I-MPH in urine and increased /MPH concentrations in blood and brain relative to dH 2 0 gavage.
(8) In mice gavaged with dl-MPH (7.5 mg/kg), concomitant ethanol (3.0 g/kg)
increased total 3 h urinary excretion of d-MPH, and increased 3 hi-MPH
concentrations in blood and brain, relative to gavage dosing with dl-MPH (7.5

mg/kg) and dH 2 0. *, P < 0.05; **, P < 0.01; ***, p < 0.001.
Figure 3.8
(A) Ethanol (3.0 g/kg, gavage at 0.25 h) and % of a 12.5 cm 2 MTS resulted in
enantioselective /-EPH formation as quantified in 3.25 h urine, blood and
brain.
(8) Concomitant gavage of ethanol (3.0 g/kg) and dl-MPH (7.5 mg/kg)
resulted in greater 3 h urinary elimination of I-EPH than for d-EPH. EPH was
not detectable (ND) in 3 h blood using dosing regimen. In brain, the mean 1EPH concentration was greater, but not significantly (NS) different from that of
d-EPH. EPH offers the potential of serving as a biomarker for combined dlMPH - ethanol exposure. *, p < 0.05; **, P < 0.01; ***, p < 0.001.
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dl-MPH and ethanol

dl-MPH and dH 20

% 12.5 cm 2 MTS

% 12.5 cm 2 MTS

+ 3.0 g/kg ethanol (gavage)

+ dH 2 0 (gavage)

n=8

n=8

Placebo patch

Placebo patch

+ 7.5 mg/kg dl-MPH
(gavage)

+ 7.5 mg/kg dJ-MPH (gavage)

+ 3.0 g/kg ethanol (gavage)

+ dH 20 (gavage)
n=8

n=8

Table 3.1 Dosing regimens for C57 mice.
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Chapter 4

Oral and transdermal dl-methylphenidate - ethanol interactions in
C57BU6J mice: Potentiation of locomotor activity with oral delivery
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Introduction
The persistent of ADHD into adulthood has been increasingly
recognized over the past few decades [4-5]. In a survey, 920/0 of adult ADHD
patients prescribed dl-MPH reported concomitant use of ethanol. Further,
1000k of individuals who obtained dl-MPH through diversion co-abused
ethanol [18]. The abuse potential of the dl-MPH - ethanol combination is well
known in the clinical literature [32-34].
Coadministration of dl-MPH and ethanol results in pharmacokinetic
and pharmacodynamic drug - drug interactions in humans [27] and in C57
(C57) mice [46, 115]. Ethanol elevates biological concentrations of the
pharmacologically active d-MPH isomer and yields the metabolic
transesterification product EPH [27, 115]. EPH appears to be formed through
the actions of carboxylesterase 1 (CES1) [27,71] which exhibits I-MPH
substrate enantioselectivity in both the metabolic transesterification and
deesterification pathways [37, 39-40] (Figure 4.1). Accordingly, the mean
absolute oral bioavailability of I-MPH is limited to only 1-30/0 compared to
approximately 30% for d-MPH [80]. However, dosing with transdermal dlMPH (Daytrana~ avoids the extensive oral presystemic metabolism and
leads to approximately 50 times more I-MPH reaching the systemic circulation
when compared with oral dosing [16].
The pharmacological significance of dosing route dependent
alterations in the relative bioavailability of d-MPH versus I-MPH was
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investigated in the present study using a C57 mouse model in the context of
ethanol interactions. The C57 mouse has served as a common reference
strain in pre-clinical investigations of psychotropic agents, including the study
of dl-MPH - ethanol interactions [40, 46, 115], as well as for the behavioral
characterization of EPH enantiomers [40-41]. As with humans, C57 mice
enantioselectively transesterify I-MPH to I-EPH [40, 115] (Figure 4.1) as well
as exhibit a biphasic excitatory-to-depressant activity profile in response to
increasing doses of ethanol [116].
A relatively low intraperitoneal (i.p.) dose of ethanol (1.75 g/kg) has
been shown to elevate motor activity for 10-15 min in C57 mice [46].
However, when this dose of ethanol was combined with a sub-stimulatory
dose of dl-MPH (1.25 mg/kg, Lp.), a potentiation of ethanol induced motor
activity occurs. As an extension of this low dose dl-MPH - ethanol behavioral
study [46], and a C57 mouse dispositional investigation where ethanol was
found to elevate blood, brain and urinary d-MPH [115] , the following
investigation examined the pharmacology of a high, otherwise motor
depressive dose of ethanol, combined with a high stimulant dose of oral or
transdermal dl-MPH. Locomotor activity counts were acquired for 3 h followed
by enantiospecific MPH and EPH brain analysis.
The influence of ethanol on the stimulant effects of dl-MPH carries
special abuse potential and adverse event liability for patients prescribed dl-
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MPH to treat ADHD, as well as for individuals obtaining dl-MPH through
diversion.

Materials and Methods

Materials
Ethanol was from AAPER Alcohol and Chemical Co. (Shelbyville, KY;
95%). dl-MPH·HCI used for oral animal studies was from Sigma-Aldrich (St.
Louis, MO; lot # 118K1052) and 12.5 cm2 transdermal dl-MPH patches
(Daytrana~ were from Shire US (VVayne, PA; lot # 2616811; smallest of 4

sizes available). Laboratory tape used to secure transdermal dl-MPH or
placebo patch (cut Band-Aid® adhesive which closely resembles the texture,
adhesion and thickness of the dl-MPH patch) was from "W-JR International
(white, 12.7 mm). dl-MPH·HCI in methanol (1 mg/mL calculated as free base;
Cerilliant, Round Rock, TX) and dl-EPH·HCI in ethanol (1 mg/mL calculated
as free base, synthesized in-house [41]) were used as the analytical
reference standards. Sodium carbonate (Fischer Scientific, Fair Lawn, NJ), nbutyl chloride (Burdick & Jackson, Muskegon, MI), acetonitrile (Mallinckrodt
Inc, Paris, KT), (S)-N-(trifluoroacetyl)prolyl choride in dichloromethane (1 M;
Sigma- Aldrich, St Louis, MO), were used for extraction and chiral
derivatization. Piperidine deuterated dl-MPH·HCI was synthesized in-house
[76] and contained approximately 250/0 of the D5-isotopolog for SIM
monitoring and containing no DO-1-MPH.
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Animals
Male C57 mice aged 8-10 weeks (25-35 g) were obtained from
Jackson Laboratories (Bar Harbor, Maine, USA). They were individually
housed in a temperature and humidity controlled colony room on a 12 h
light/dark cycle (light: 07.00-19.00 h) with free access to food and water. All
experiments were approved by and conducted within the guidelines of the
Institutional Animal Care and Use Committee at the Medical University of
South Carolina and followed the guidelines of the NIH Guide for the Care and
Use of Laboratory Animals (NIH Publication no. 80-23, revised 1996).

Locomotor Activity and Analysis
Apparatus
Motor activity was assessed with a Digiscan Animal Activity Monitor
system, model RXYZCM(8) TAO with a two-animal option (Omnitech
Electronics, Columbus,Ohio, USA). Each activity chamber contained 2 arrays
of 16 photo beams spaced 5 cm apart, with eight beams located on the x-axis
and eight on the y-axis. One array was located 1.5 cm above floor level to
capture horizontal activity and the other was located 6.5 cm above the floor to
capture vertical activity of the mice. Stereotypic counts were recorded when
the same beam was repeatedly interrupted. Photocells were activated when
the photo beams on the wall directly opposite to the cells were interrupted.
The Versadat analyzer (Version 2.70-137E) recorded the interruption of each
beam and provided the total distance (cm) and vertical activity for each
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animal during testing. Each activity chamber was partitioned into 20 x 20 cm
quadrants with acrylic dividers to allow simultaneous testing of two mice.
Four activity chambers allowed testing of eight mice per session. Each of the
activity chambers were enclosed in 90 x 54 x 35 cm sound-attenuated boxes.
Procedures for locomotor activity assessment
On days 1-3, mice were habituated to the motor activity apparatus for
30 min. On day 4 mice were lightly anesthetized with 5% isofluorane for 8-10
min. The hair was clipped with an electric shaver along the abdomen and
back, from shoulders to hips. A placebo patch was placed on the lower left
hip and secured by laboratory tape over the patch and around the mouse for
one full loop to ensure a constant skin interface and to prevent the mice from
disturbing the patch. Mice were then gavaged at a volume of 0.02 mUg body
weight with deionized water (dH 2 0) and placed in the open-field activity
chambers for 3 h. On Day 5, mice were randomly placed into 1 of 6 test
groups (all with n = 8): placebo patch + dH 2 0, placebo patch + ethanol,
placebo patch + oral dl-MPH + dH 2 0, placebo patch + oral dl-MPH + ethanol,
transdermal dl-MPH + dH 2 0, or transdermal dl-MPH + ethanol. Oral dl-MPH
was dosed as the Hel salt using 7.5 mg/kg calculated as the free base. This
dose was the mean dose absorbed by

~

patch as established by drug load

difference between an unused versus used mouse patch study [115]. Each
animal was anesthetized and either a placebo patch or % of 12 cm 2
transdermal patch was placed around the midsection in the same manner as
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day 4. They were gavaged at a volume of 0.02 mUg body weight with either
dH 20 or ethanol (3.0 g/kg) and placed in the activity apparatus for 3 h.
Following the conclusion of the locomotor activity session, animals were
sacrificed and brain samples collected.
The order of treatment groups within each week, and the particular test
chamber used to test the different groups was counterbalanced across the
entire experiment to eliminate any contribution of possible differences in
activity monitors or days of testing to observed effects on motor activity. Total
distance and vertical activity were recorded in 5-min bins for the entire 3 h
session.
Locomotor Activity Data Analysis
Locomotor activity data in Figures 4.2 and 4.3 was grouped into 20
bins and analyzed using a mixed factor three-way analysis of variance
(ANOVA). Oral dl-MPH data and transdermal dl-MPH data were analyzed
separately using a 2(dl-MPH dose) X 2(ethanol dose) X 9(TimeBin) design.
The between groups factors are dl-MPH (dH 20 vs. active dose) and ethanol
(dH20 vs. active dose). The repeated measure is TimeBin. When
appropriate, post-hoc comparisons of significant main effects or factor
interactions were made using pair-wise comparisons with Bonferroni's
correction. Statistical analysis was conducted using PASW Statistics 18
(SPSS Inc., Chicago, Illinois, USA).
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Brain MPH and EPH analysis

Enantiospecific analysis of d-, I-MPH and d-, I-EPH was conducted as
previously described in a recent dl-MPH - ethanol disposition report [115] .
Briefly, homogenized and alkalinized 1/2 brains were solvent extracted and
after chiral derivatization, the samples were injected into a gas
chromatograph - mass spectrometer fit with a 5% phenylmethylpolysiloxane
column. The trifluoroprolylpiperidyl electron impact fragment ions from
analytes and the deuterated dl-MPH internal standard were acquired using
selected ion monitoring. A range of spiked blank brain calibrators bracketed
all concentrations reported as established by linear regression analysis (~ >

0.99).
Brain Concentration Data Analysis

A two way analysis of variance (ANOVA) followed by pair wise
comparisons using the Student's t-test method was used in the analysis of all
data. Samples were analyzed as independent samples and were assumed to
have equal variances. Statistical analysis was conducted using SPSS 12.0
(SPSS I.; Chicago, Illinois, USA).

Results
Controls

Mice treated with placebo patches + ethanol (3.0 g/kg) showed
Significantly less total distance traveled compared to mice treated with
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placebo patch + dH 20 over the first 100 min (all ps<O.05) and significantly less
vertical activity for the entire 3 h (all ps<O.01).

Total Distance Traveled
Oraldl-MPH
The total distance traveled data was analyzed by examining changes
in horizontal activity across time for the different treatment groups and is
summarized in Figure 4.2A. A significant 3 way interaction was found
(F(8,224)= 10.906, P <0.001). Post-hoc analysis indicated a significant
increase in total distance traveled for oral dl-MPH + dH 20 compared to the
placebo patch + dH 20 for the first 1 h (all ps<O.05). Further, total distance
traveled for the oral dl-MPH + ethanol group was significantly greater than
oral dl-MPH + dH20 group over the first 100 min (all ps<O.5).

Transdermal dl-MPH
The total distance traveled data was analyzed by examining changes
in horizontal activity across time for the different treatment groups and are
summarized in Figure 4.3A. The 3 way interaction was not significant for the
transdermal dl-MPH group. However, the lower level 2 way interactions were
significant for TimeBin vs. ethanol (F(8,224)=5.27, p<O.001) and TimeBin vs.
dl-MPH (F(8,224)=28.07, p<O.001). Post hoc analysis indicated a significant
increase in total distance traveled for the transdermal

dl-MPH + dH20 group

compared to the placebo patch + dH20 group over the 100-180 min time
period (all ps<O.01).
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Vertical Activity

Oraldl-MPH
The vertical activity data was analyzed by examining changes in
activity across time for the different treatment groups and is summarized in
Figure 4.2B. A significant 3 way interaction was found (F(8,224)=207.747, p
<0.001). Post-hoc analysis indicated a significant increase in vertical activity

for oral dl-MPH + dH20 compared to the placebo patch + dH 20 for the first 100
min (all ps<O.05). Vertical activity data for mice dosed with oral dl-MPH +
ethanol and mice dosed with placebo patch + ethanol were significantly
decreased compared to the placebo patch + dH 20 and oral dl-MPH + dH 2 0 for
the entire 3 h (all ps<0.001).

Transdermal dl-MPH
The vertical activity data was analyzed by examining changes in activity
across time for the different treatment groups and is summarized in Figure
4.38. A significant 3 way interaction was found (F(8,224)=34.935, p <0.001).
Post-hoc analysis indicated a significant increase in vertical activity for
transdermal dl-MPH + dH20 compared to the placebo patch + dH 2 0 100-180
min (all ps<O.01). Vertical activity data for mice dosed with transdermal dlMPH + ethanol and mice treated with placebo patch + ethanol were
significantly decreased compared to placebo the patch + dH 2 0 and
transdermal dl-MPH + dH20 groups for the entire 3 h (all ps<O.001).
Brain Drug and Metabolite Concentrations
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Oraldl-MPH
The brain concentration of d-MPH following oral dl-MPH was
significantly greater in the animals dosed with ethanol compared to those
given dH20; increasing from 31 ng/g to 51 ng/g (Figure 4.4A; t = 3.92, df = 14,
p<O.001). Further, in animals dosed with oral

dl-MPH, concentrations of 1-

MPH were significantly increased from 33 ng/g for animals dosed with dH20 to
42 ng/g for animals dosed with concomitant ethanol (Figure 4.4A; t

=2.24, df

= 14, p<O.05). There were no significant differences between the brain
concentrations of d-MPH and I-MPH in animals dosed with dH 20 or in animals
dosed with ethanol. Only the I-isomer of EPH was detected in animals
gavaged with ethanol and was found at a concentration of 10 ng/g (Figure
4.4A).

Transdermal dl-MPH
The brain concentration of d-MPH after transdermal dosing was
significantly greater in animals dosed with ethanol compared the dH 20 group;
increasing from 689 ng/g to 1,294 ng/g (Figure 4.48; t = 7.38, df =14,
p<O.001). Further, in animals dosed with transdermal dl-MPH, concentrations

of I-MPH were significantly increased by ethanol, rising from 685 ng/g for
animals dosed with dH 20 to 1,210 ng/g for animals dosed with ethanol (Figure
4.48; t = 7.689, df =14, p<O.001). There were no significant differences
between the brain concentration of d-MPH and I-MPH in animals dosed with
dH 20, nor in animals dosed with ethanol. Only the I-isomer of EPH was

69

detected in animals gavaged with ethanol and was found at a mean
concentration of 130 nglg (Figure 4.48).

Discussion
Most oral dl-MPH abusers coabuse ethanol [18] and the abuse potential of
the dl-MPH - ethanol combination is well known in the clinical literature [3234]. In the present study, C57 mice were used to model pharmacological
characteristics of this drug combination to gain insight into the special appeal
this drug combination has. The abuse potential of the new transdermal dlMPH formulation has not been investigated in detail at this time. In industry
trials, transdermal dl-MPH been has reported to produce mild euphoria upon
application of 3 or 6 of the 25 cm 2 patches. With the 6-patch application group
dysphoria was reported in 42% of the test subjects. It is noted that the FDA
requested human testing by the contraindicated application of the patch to
buccal mucosa. This tissue surface greatly accelerated dl-MPH absorption
relative to the normal hip application. Rather than the mean 36% of the patch
dl-MPH content being absorbed during the recommended 9 h wear, 50% was
absorbed in 2 h attached in the mouth (see Patrick et al. 2009).
We have previously reported that a sub-stimulatory Lp. dose of dl-MPH in
C57 mice potentiates the motor stimulation produced by a low dose of ethanol
[46]. The present study used stimulatory oral or transdermal doses of dl-MPH
(7.5 mg/kg), with or without a depressive dose of ethanol (3 g/kg) to model
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dosing route dependent behavioral and dispositional drug interactions as may
pertain to both the treatment of adult ADHD patients who use or abuse
ethanol and the co-abuse pharmacology of diverted dl-MPH and ethanol.
The findings in the present study demonstrate that even a depressive dose
of ethanol potentiates a stimulatory dose of oral dl-MPH. This potentiation
may result from both pharmacokinetic and pharmacodynamic interactions.
The 7.5 mg/kg doses of dl-MPH used in the present study approaches the
highest daily doses found in the medical drug abuse literature, e.g.,
approximately 10 mg/kg/day intranasally [117] or 29 mg/kg/day intravenously
[118] based on 70 kg total body weight (actual weights were not reported).
While these doses were reported as total daily doses and the dosing
"regimen" undisclosed, the intranasal route and certainly the intravenous
routes are expected to result in higher bioavailability than following oral
dosing. For instance, only 19% of an oral dl-MPH dose reaches the systemic
circulation in rats [119] versus approximately 300/0 in humans [79]. Further, a
transdermal dose of dl-MPH is absorbed in a prolonged fashion analogous to
a multiple dose regimen as the abusers above were likely to have used.
The ethanol dose of 3 g/kg used in this study corresponds to 10 ounces of
80% vodka in a 70 kg human, well within the range of ethanol consumption
associated with bingeing. The choice of a 3 g/kg dose allowed comparisons
with the urinary metabolites, blood and brain concentrations of dl-MPH and
dl-EPH found in the previous metabolism study [115]. Further, this dose
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allowed us to indirectly gauge probable concentrations of ethanol over the
course of the present behavioral studies through comparison with literature
values in C57 mice. Haseba et al. (2007) found the peak ethanol
concentration to be 322 mg% at 0.5 h, declining to approximately 35 mg% 3 h
after oral dosing.
Ethanol has been shown to significantly increase the maximum plasma
concentration and total exposure to d-MPH and I-MPH in humans [27], as well
as elevate d-MPH and I-MPH blood, brain and urine concentrations in the
C57 mouse [115]. The present brain d-MPH, I-MPH and I-EPH
determinations are concordant with our earlier reported brain concentrations
[115]. At the 3 h sacrifice time, the mean d-MPH brain concentration was 23
times higher in the transdermal group than in the oral dosing group without
ethanol. Upon co-administration of ethanol, there was an 880/0 elevation of dMPH in the transdermal group and 660/0 elevation following oral dl-MPH at the
3 h time point.
At the pharmacodynamic level, the potentiation of dl-MPH induced
behavioral effects may be based on the mutual influence of these drugs on
dopamine, i.e., both d-MPH and ethanol have been reported to elevate
synaptic dopamine levels. The therapeutic activity of the stimulant dl-MPH in
the treatment of ADHD prominently involves the reuptake blockade of impulse
released dopamine through binding to the dopamine transporter [120]. In our
animal model of dl-MPH - ethanol co-abuse, the potentiation of stimulatory
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effects by concomitant ethanol is consistent with evidence that ethanol
releases pre-synaptic dopamine [121-122] as a consequence of upstream
GABAergic signaling [123]. Hence ethanol may be increasing extracellular
dopamine release, whereby d-MPH then blocks a larger dopamine pool from
presynaptic reuptake. Further, ethanol-mediated dopamine release
significantly increases as the ethanol dose (i.p.) is escalated from 1 g/kg to 2
g/kg to 3 g/kg in C57 mice [122]; the 3 g/kg of ethanol corresponding to the
oral dose used in the present study_ In this context, we hypothesize that the
increased locomotor activity resulting from concomitant oral dl-MPH and an
otherwise depressive dose of ethanol may reflect a synergistic increase in
synaptic dopamine, modeling the accentuation of likeability associated with
dl-MPH combined with ethanol when compared to dl-MPH alone [27].
In humans, the earliest detection of either MPH isomer in plasma after
transdermal dl-MPH application ranges from 1-6 h [91], unlike oral dl-MPH
which is readily detectable within 30 min or less [124-125]. The significantly
lower total distance traveled of mice dosed with transdermal dl-MPH
compared to oral dl-MPH is likely influenced by a lag phase (latency) in
transdermal drug absorption during which time locomotor activity of mice
inherently decreases as habituation to the activity chamber occurs. We report
here that the lag phase between application of the transdermal dl-MPH patch
and the onset of pronounced drug-induced motor activity is approximately 100
min in C57 mice. Studies in C57 mice have shown that d- and dl-MPH

73

produce dose-related increases in motor activity, while the I-isomer produces
little or no stimulatory effects [40]. Thus, it is hypothesized that despite
significantly higher 3 h brain concentrations of d-MPH following transdermal
dosing, the total distance traveled of mice did not reach the same levels of
early time points following oral dosing due in part to the mice habituating to
the chambers and such low activity was not able to rebound to early activity
levels found after oral dosing. A further explanation for the attenuated total
distance traveled by the transdermal dl-MPH - ethanol group could pertain to
the induction of stereotypic behaviors associated with such high brain d-MPH
concentrations, especially in the concomitant ethanol group. This may be
supported by the significantly higher vertical activity found at later time points
following transdermal dosing. Further, the observation that the stimUlant
effect of transdermal dl-MPH was not potentiated by co-administration of
ethanol may relate to the anticipated lag phase in transdermal drug
absorption extending well into the elimination phase of ethanol (see [115]. It is
noted that the mean elimination half-life of ethanol in C57 mice has been
reported to be approximately 1.3 h to 1.5 h [122, 126].
The 13-fold greater I-EPH concentration found in the transdermal dl-MPH
- ethanol group relative to the oral dl-MPH - ethanol group is unlikely to
directly contribute to the neuropharmacology of this drug combination in view
of the inactivity of the I-isomer of EPH in vivo or in vitro [40-41]. However, the
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/-EPH concentration may indirectly gauge the extent to which dl-MPH and
ethanol interact with CES1.
The presence of /-EPH in the C57 mouse brain samples offers further
evidence that this transesterification metabolite can serve as a biomarker for
concomitant dl-MPH - ethanol exposure [72]. Most importantly, ethanol
significantly potentiated oral dl-MPH induced stimulant effects and elevated
the brain d-MPH concentrations in this C57 mouse model. These findings
could carry implications for increased abuse liability when ethanol is
combined with dl-MPH should this model generalize to humans.
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Figure Legends
Figure 4.1
Enantioselective de-esterification of dl-MPH to ritalinic acid (top right) and
transestification to l-ethylphenidate.

Figure 4.2
(A) Oral dl-MPH + dH2 0 significantly increased total distance traveled (*,
p<O.05) and this effect was potentiated by a depressive dose of ethanol (+,
p<O.05).

(8) Oral dl-MPH significantly increased vertical activity of mice over the first

100 min (*, p<O.05).
Figure 4.3
(A) Transdermal dl-MPH induced locomotor activity after a lag phase of 100
min (**, p<O.01). While this effect was not potentiated by ethanol,
transdermal dl-MPH + ethanol was significantly greater than placebo patch +
dH 20 after a lag phase of 140 min (++, p<O.01).
(8) Transdermal dl-MPH significantly increased vertical activity of mice after
100 min lag time (*, p<O.05).

Figure 4.4
(A&B) Ethanol significantly increased brain concentrations of d-MPH and /MPH relative to dH20 in mice dosed orally or transdermally (*, p<O.05; ***,
p<O.001).
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Chapter 5

Summary and Conclusions
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Summary
The purpose of the experiments in this dissertation was to develop a
mouse model to investigate the reward value of dl-MPH and the
pharmacokinetic and pharmacodynamic interactions with ethanol. Previous
studies have used IP injections as a route of administration to investigate dlMPH and ethanol interactions, but the current studies used routes of
administration similar to how a normal ADHD patient would consume his or
her drugs with a particular focus on the transdermal route of administration for
dl-MPH and oral administration of ethanol.
In huma.ns, coadministration of dl-MPH and ethanol results in a
significant elevation of maximum plasma d-MPH concentrations (Cmax) and
overall d-MPH exposure [27]. Elevated plasma d-MPH concentrations
increase the potential for adverse cardiovascular events [42-43] due to the
fact that the d-isomer is responsible for adrenergic pressor effects. In
addition to the influence of ethanol on dl-MPH pharmacokinetics, the above
normal subjects reported an increase in pleasurable effects when combining
dl-MPH with ethanol [44]. Such positive subjective effects may predispose
individuals to greater abuse liability [32-33, 45].
To better understand the pharmacokinetic and pharmacodynamic
interactions between dl-MPH and ethanol, we first established that C57 mice
are a valid model for investigating the reward value of dl-MPH. We then used
C57 mice to investigate the following research questions: 1) To what degree
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does ethanol influence the concentration of enantiomers of MPH and EPH in
the brain, blood or urine of C57 mice? 2) What effect does ethanol have on
the stimulatory effects of dl-MPH in C57 mice? 3) Is there a differential effect
of ethanol on C57 mice dosed with oral dl-MPH versus transdermal MPH?
Results from Specific Aim 1 confirmed that C57 mice self-administer
dl-MPH and exhibit robust drug seeking behavior in response to the drug itself
and conditioned cues. Previous studies using the Spontaneously
Hypertensive Rat as a model for ADHD show that they do exhibit drug
seeking behavior [50], however growing evidence suggests they are not an
appropriate model for ADHD particularly in their response to first line
therapeutics such as dl-MPH [51-52]. The C57 mouse is a widely used
reference strain for drugs of abuse [40-41, 46, 55] and was chosen as the
preferred model for studying dl-MPH, particularly with coadministration of
ethanol in view of the fact that this strain prefers to consume ethanol [127].
The C57 mouse model has been shown to self-administer cocaine [56] and in
the present study has been shown to quickly acquire drug seeking behavior of
dl-MPH. In this study, self-administration is maintained despite increasingly
difficult demands. The reward value of dl-MPH is shown through robust drugseeking behavior despite a two week abstinence period and the lack of drug
reinforcement. It is further shown through the maintenance of drug seeking
behavior despite removal of condition cues implying that drug seeking
behavior in this study was not due to a condition response, but actually due to
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the reward value of dl-MPH. The results of this study indicate that the C57
mouse is an appropriate model for further studies using dl-MPH.
Results from Specific Aim 2 indicated that ethanol significantly altered
the pharmacokinetics of dl-MPH in C57 mice, particularly when dosing by the
transdermal route. A quarter of the smallest commercially available MTS patch
was used and this delivered a mean dose of -7.5 mg/kg of dl-MPH over the
3.25 h wear period based on the difference between drug content before and
after application. Though the MTS is not designed to be cut into portions for
clinical applications, the dl-MPH content in each patch is evenly distributed
throughout the patch [16] and required apportioning when using such a small
species as the mouse. The mean dose of 0.23 mg of dl-MPH delivered to the
mice (n

= 12) over the 3.25 h wear represents 3.3% of the % patch content of

dl-MPH and ranged from 1.9 - 5.10/0. In humans, the uncut 12.5 cm 2 patch size
is deSigned to deliver a mean dl-MPH dose of 10 mg over the recommended 9
h wear. This dose represents 36% of the patch dl-MPH content, though
ranging between subjects from 15-72% [89]. The apparent transdermal dl-MPH
absorption differences reflect many factors including: (1) the shorter wear time
of 3.25 h for the mouse, (2) the faster rate of ester substrate metabolism
expected with rodents relative to humans [90], (3) the hair follicle rich shaved
skin of the mice opposed to the skin surface of the recommended hip
placement in clinical applications, and (4) the potential for a greater relative
absorption lag time for the 3.25 h wear versus 9h in humans. In this latter
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context, the average lag time for detectable d-MPH in plasma after applying
MTS to humans is 3.1 h (ranging from 1-6 h)[91]. The above factors
notwithstanding, it is recognized that the percutaneous absorption rate for a
range of drugs in mice and other rodents has generally been found to be more
rapid than in humans or pigs [92].
Our studies with mice dosed with oral dl-MPH+dH20, while being limited to
a single 3 h time point for blood and brain sampling, suggest a lower degree of
metabolic enantioselectivity relative to humans, whereby the d-MPH-to-I-MPH
ratio for blood and brain were 1.22 and 1.36, respectively. This apparent
greater oral bioavailability of I-MPH in the C57 mouse than in man is in general
agreement with plasma results using CD1 mice dosed at 5.0 mg/kg [86] or
pregnant rats dosed at 7.0 mg/kg [87]. Further, the extent of accumulation in
brain relative to blood will be expected to be less dramatic at 3 h than at earlier
time points, especially after oral dosing were the decay time course to resemble
that of the Sprague-Dawley rat [77].
Based on human investigations [27], and the present findings with C57
mice, the enantioselective formation of /-EPH following co-administration of
dl-MPH and ethanol is accompanied by an elevation in d-MPH concentrations
relative to dosing with dl-MPH alone. While /-EPH formation was found to be
enantioselective, this metabolic pathway was not enantiospecific, i.e., /-EPH
concentrations significantly exceeded d-EPH values though d-EPH was
readily detectable and quantifiable in C57 mouse samples following MTS and
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ethanol, as well as in the urine of animals dosed orally with dl-MPH. In
humans dosed orally with dl-MPH and ethanol, d-EPH rarely exceeded 100/0
of the concentration of I-EPH [27]. In potential forensic medicine applications
[72], detection of EPH from biological samples could serve as a biomarker to
demonstrate combined consumption of dl-MPH and ethanol; analogous to the
detection of cocaethylene as evidence of cocaine - ethanol coabuse [100]. In
view of the significant influence of ethanol on d-MPH concentrations in the
C57 mouse model reported here, transdermal dl-MPH used to treat adult
ADHD may be associated with clinical considerations unique to this route of
administration, should drug interaction findings from of this animal model hold
for humans.
Results from Specific Aim 3 indicated that that a depressive dose of
ethanol potentiates a stimulatory dose of oral dl-MPH. This provides
additional insight into the reward value associated with dl-MPH - ethanol coabuse (see [18] and [115]). The ethanol -mediated increases in d-MPH brain
concentrations found following oral dosing, and the potentiated behavioral
effects, carry special abuse liability implications for the dl-MPH - ethanol
combination [18].
The significantly lower total distance traveled of mice dosed with
transdermal MPH compared to oral dl-MPH is likely due to the lag phase in
transdermal drug absorption [16] as well as the fact that locomotor activity of
mice decreases over time. It is hypothesized that despite significantly higher
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3 h brain concentrations of the d-isomer of MPH following transdermal dosing,
the total distance traveled of mice (while significant compared to transdermal
dl-MPH + dH 2 0) did not reach the same levels of early time points following
oral dosing due to the fact that mice had reached such low activity that the
rebound effect was not able to reach levels found after oral dosing. A further
explanation could be potential stereotypic behaviors associated with such
high brain d-MPH concentrations and may be reflected in the significantly
higher vertical activity found at later time points following MTS dosing.
Further, the observation that the stimulant effect of transdermal dl-MPH was
not potentiated by co-administration of ethanol is interpreted as a lag phase in
transdermal dl-MPH drug overlapping the elimination phase of the oral
ethanol (see [115]).
The presence of I-EPH in the C57 mouse brain samples offers further
evidence that this transesterification metabolite can serve as a biomarker for
concomitant dl-MPH - ethanol exposure [72].
The results from these studies in combination with human clinical data
indicate that concomitant ethanol significantly alters the pharmacokinetics and
pharmacodynamics of dl-MPH alone. These interactions have significant
implications for abuse liability and toxicity and should be considered before
prescribing the stimulant medication dl-MPH to an adult population.
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